



## **Media Alert**

### **Merrimack Pharmaceuticals to Present at the 28<sup>th</sup> Annual JPMorgan Healthcare Conference**

**CAMBRIDGE, Mass.**, January 6, 2010 – Merrimack Pharmaceuticals today announced that it will present at the 28<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco. Bob Mulroy, President and Chief Executive Officer, will provide a company overview at 2:00pm PST, Tuesday, January 12, 2010 at the St. Francis Hotel in San Francisco, California.

#### **About Merrimack**

Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack's first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts.

#### **Contacts**

Kathleen Petrozzelli, Corporate Communications, 617-441-1043, [kpetrozzelli@merrimackpharma.com](mailto:kpetrozzelli@merrimackpharma.com),  
<http://www.merrimackpharma.com>  
Betsy Raymond Stevenson, RaymondStevenson Healthcare Comms, 860-984-1424,  
[betsy@raymondstevenson.com](mailto:betsy@raymondstevenson.com)

# # #